Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Ian Clark sold 28,611 shares of Guardant Health stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $107.19, for a total value of $3,066,813.09. Following the transaction, the director owned 9,851 shares of the company's stock, valued at $1,055,928.69. The trade was a 74.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Guardant Health Stock Up 2.1%
Shares of GH opened at $104.17 on Tuesday. The company has a market capitalization of $13.13 billion, a price-to-earnings ratio of -32.45 and a beta of 1.58. Guardant Health, Inc. has a 52 week low of $29.91 and a 52 week high of $112.43. The stock's 50-day moving average price is $85.51 and its 200-day moving average price is $63.90.
Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. During the same period last year, the company earned ($0.88) earnings per share. Guardant Health's revenue was up 38.5% on a year-over-year basis. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of GH. Cetera Investment Advisers purchased a new stake in Guardant Health during the 1st quarter worth approximately $211,000. Natixis Advisors LLC purchased a new position in shares of Guardant Health in the first quarter valued at approximately $984,000. PNC Financial Services Group Inc. boosted its stake in shares of Guardant Health by 25.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock worth $112,000 after acquiring an additional 537 shares during the last quarter. Invesco Ltd. increased its position in shares of Guardant Health by 100.9% during the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company's stock worth $119,053,000 after purchasing an additional 1,403,670 shares in the last quarter. Finally, Aigen Investment Management LP increased its position in shares of Guardant Health by 9.0% during the first quarter. Aigen Investment Management LP now owns 28,298 shares of the company's stock worth $1,205,000 after purchasing an additional 2,341 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $60.00 to $70.00 and gave the stock an "overweight" rating in a report on Thursday, September 25th. Barclays upped their price objective on shares of Guardant Health from $70.00 to $85.00 and gave the stock an "overweight" rating in a research report on Thursday, October 30th. UBS Group raised their target price on Guardant Health from $80.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, October 30th. Cowen restated a "buy" rating on shares of Guardant Health in a research note on Thursday, October 30th. Finally, Wells Fargo & Company initiated coverage on Guardant Health in a research report on Monday, September 22nd. They set an "overweight" rating and a $72.00 price target on the stock. Twenty-three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Guardant Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $80.86.
Get Our Latest Research Report on Guardant Health
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
